Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Roher, Alex E ^a   Cribbs, David H ^b,c   Kim, Ronald C ^c   Maarouf, Chera L ^a   Whiteside, Charisse M ^a   Kokjohn, Tyler A ^a,d   Daugs, Ian D ^a   Head, Elizabeth ^e   Liebsack, Carolyn ^a   Serrano, Geidy ^a   Belden, Christine ^a   Sabbagh, Marwan N ^a   Beach, Thomas G ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MIDWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MALE; PROTEIN SYNTHESIS; TEMPORAL LOBE; UPREGULATION; VASCULAR AMYLOIDOSIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; PEPTIDE FRAGMENTS; TAU PROTEINS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84875317231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059735     Document Type: Article

References (99)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
2. Pul R, Dodel R, Stangel M, (2011) Antibody-based therapy in Alzheimer's disease. Expert Opin Biol Ther 11: 343-357.
3. Morgan D, (2011) Immunotherapy for Alzheimer's disease. J Intern Med 269: 54-63.
4. Kerchner GA, Boxer AL, (2010) Bapineuzumab. Expert Opin Biol Ther 10: 1121-1130.
5. Maarouf CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, et al. (2010) The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener 5: 39.
6. Boche D, Zotova E, Weller RO, Love S, Neal JW, et al. (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131: 3299-3310.
7. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223.
8. Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, et al. (2010) Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 133: 1312-1327.
9. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, et al. (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169: 1048-1063.
10. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
11. Fagan T (2012) Clinical Trials of Intravenous Bapineuzumab Halted. Available: http://www.alzforum.org/new/detail.asp?id=3234. Accessed 15 October 2012.
12. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070.
13. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, et al. (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 9: 229-245.
14. Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, et al. (2011) Neuropathology and Aβ Spectrum in a Bapineuzumab Immunotherapy Recipient. J Alzheimers Dis 24: 315-325.
15. Mirra SS, (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging 18: S91-S94.
16. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
17. Sabbagh MN, Cooper K, DeLange J, Stoehr JD, Thind K, et al. (2010) Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res 7: 280-286.
18. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, et al. (2003) Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 23: 2055-2062.
19. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 18: S1-S2.
20. Head E, Azizeh BY, Lott IT, Tenner AJ, Cotman CW, et al. (2001) Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome. Neurobiol Dis 8: 252-265.
21. Saing T, Dick M, Nelson PT, Kim RC, Cribbs DH, et al. (2012) Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma 29: 1054-1070.
22. Head E, Starr A, Kim RC, Parachikova A, Lopez GE, et al. (2006) Relapsing polychondritis with features of dementia with Lewy bodies. Acta Neuropathol 112: 217-225.
23. Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, et al. (2011) Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One 6: e27291.
24. Chaney MO, Webster SD, Kuo YM, Roher AE, (1998) Molecular modeling of the Abeta1-42 peptide from Alzheimer's disease. Protein Eng 11: 761-767.
25. Zhang Y, Kim B-H, Yu J, Lovas S, Lyubchenko Y, (2012) Molecular mechanisms of beta-amyloid misfolding and aggregation: Insights from experiments and theory. Alzheimers Dement 8: P659.
26. Kim BH, Palermo NY, Lovas S, Zaikova T, Keana JF, et al. (2011) Single-molecule atomic force microscopy force spectroscopy study of Abeta-40 interactions. Biochemistry 50: 5154-5162.
27. Lyubchenko YL, Kim BH, Krasnoslobodtsev AV, Yu J, (2010) Nanoimaging for protein misfolding diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2: 526-543.
28. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, et al. (1993) Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268: 3072-3083.
29. Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, et al. (1994) Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 269: 10987-10990.
30. Kuo YM, Emmerling MR, Woods AS, Cotter RJ, Roher AE, (1997) Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 237: 188-191.
31. Kuo YM, Webster S, Emmerling MR, De LN, Roher AE, (1998) Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim Biophys Acta 1406: 291-298.
32. Kokjohn TA, Maarouf CL, Roher AE, (2012) Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray? Alzheimers Dement 8: 574-583.
33. Atwood CS, Bowen RL, Smith MA, Perry G, (2003) Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res Brain Res Rev 43: 164-178.
34. Cullen KM, Kocsi Z, Stone J, (2006) Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging 27: 1786-1796.
35. Cullen KM, Kocsi Z, Stone J, (2005) Pericapillary haem-rich deposits: evidence for microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab 25: 1656-1667.
36. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, et al. (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7: 367-385.
37. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, et al. (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11: 241-249.
38. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, et al. (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24: 198-203.
39. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, et al. (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9: 363-372.
40. Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, et al. (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7: 396-401.
41. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, et al. (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298: 1379.
42. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN, (2007) Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144: 950-960.
43. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, et al. (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1: 24.
44. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, et al. (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25: 629-636.
45. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, et al. (2005) Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 167: 527-543.
46. Luo F, Rustay NR, Seifert T, Roesner B, Hradil V, et al. (2010) Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice. J Pharmacol Exp Ther 335: 580-588.
47. Strobel G (2012) Expanding the Network, DIAN Starts Showing Longitudinal Data. Available: http://www.alzforum.org/new/detail.asp?id=3290. Accessed 15 October 2012.
48. Gama Sosa MA, Gasperi RD, Rocher AB, Wang AC, Janssen WG, et al. (2010) Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations. Am J Pathol 176: 353-368.
49. Goodman J, Freeman G, Angus W, Brown T, Cheng-te Chou P, et al. (2012) Spontaneous amyloid-related imaging abnormalities of the microhemorrage and effusive/edematous types in aged APP+ presenilin 1 mice. Alzheimers Dement 8: P11-P12.
50. Goodman J, Freeman G, Angus W, Brown T, Cheng-te Chou P, et al. (2012) Spontaneous ARIA-E and ARIA-H in Aged APP+PS1 Mice. Alzheimers Dement 8: P153.
51. Zlokovic BV, (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12: 723-738.
52. Kalaria RN, (2010) Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 68Suppl 2: S74-S87.
53. Craft S, (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66: 300-305.
54. Nag S, Kapadia A, Stewart DJ, (2011) Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol 37: 3-23.
55. Shlosberg D, Benifla M, Kaufer D, Friedman A, (2010) Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 6: 393-403.
56. Kalaria RN, Akinyemi R, Ihara M, (2012) Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 1322: 141-147.
57. Hachinski V, Kalaria RN, Deramecourt V, (2012) Staging and natural history of cerebrovascular pathology in dementia. Neurology 79: 107.
58. de la Torre JC (2012) Cerebral Hemodynamics and Vascular Risk Factors: Setting the Stage for Alzheimer's Disease. J Alzheimers Dis.
59. Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, et al. (2010) Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 77: 82-102.
60. Kuo YM, Shih YH, Lee CW, Jiang MJ, Lin PY, (2012) Hypertension increases tau hyperphosphorylation and beta-amyloid production in pigs. Alzheimers Dement 8: P651.
61. Tougu V, Tiiman A, Palumaa P, (2011) Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. Metallomics 3: 250-261.
62. Kenche VB, Barnham KJ, (2011) Alzheimer's disease & metals: therapeutic opportunities. Br J Pharmacol 163: 211-219.
63. Chuang JY, Lee CW, Shih YH, Yang T, Yu L, et al. (2012) Interactions between amyloid-beta and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease. PLoS One 7: e33120.
64. Roberts BR, Ryan TM, Bush AI, Masters CL, Duce JA, (2012) The role of metallobiology and amyloid-beta peptides in Alzheimer's disease. J Neurochem 120Suppl 1: 149-166.
65. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, et al. (1993) beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A 90: 10836-10840.
66. Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, et al. (1999) Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 274: 15990-15995.
67. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, et al. (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271: 32916-32922.
68. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, et al. (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268: 750-756.
69. Milojevic J, Melacini G, (2011) Stoichiometry and affinity of the human serum albumin-Alzheimer's Abeta peptide interactions. Biophys J 100: 183-192.
70. Xi G, Reiser G, Keep RF, (2003) The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem 84: 3-9.
71. Matsuoka H, Hamada R, (2002) Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention? CNS Drugs 16: 509-516.
72. Grammas P, Ottman T, Reimann-Philipp U, Larabee J, Weigel PH, (2004) Injured brain endothelial cells release neurotoxic thrombin. J Alzheimers Dis 6: 275-281.
73. Yin X, Wright J, Wall T, Grammas P, (2010) Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am J Pathol 176: 1600-1606.
74. Gingrich MB, Traynelis SF, (2000) Serine proteases and brain damage- is there a link? Trends Neurosci 23: 399-407.
75. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, et al. (2010) Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A 107: 21812-21817.
76. Melchor JP, Pawlak R, Chen Z, Strickland S, (2003) The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer's disease. J Mol Neurosci 20: 287-289.
77. Melchor JP, Pawlak R, Strickland S, (2003) The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 23: 8867-8871.
78. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, et al. (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 66: 695-709.
79. Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD, (1991) Platelet protease nexin-2/amyloid beta-protein precursor. Possible pathologic and physiologic functions. Ann N Y Acad Sci 640: 140-144.
80. Van Nostrand WE, Schmaier AH, Wagner SL, (1992) Potential role of protease nexin-2/amyloid beta-protein precursor as a cerebral anticoagulant. Ann N Y Acad Sci 674: 243-252.
81. Abraham CR, Potter H, (1989) The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease. Ann Med 21: 77-81.
82. Abraham CR, McGraw WT, Slot F, Yamin R, (2000) Alpha 1-antichymotrypsin inhibits A beta degradation in vitro and in vivo. Ann N Y Acad Sci 920: 245-248.
83. Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, et al. (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133: 3336-3348.
84. Boche D, Denham N, Holmes C, Nicoll JA, (2010) Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120: 369-384.
85. Fagan T (2011) Pfizer Halts Development of Aß Antibody. Available: http://www.alzforum.org/new/detail.asp?id=2950. Accessed 15 October 2012.
86. Zakaib GD (2012) Phase 3 Solanezumab Trials 'Fail'-Is There a Silver Lining? Available: http://www.alzforum.org/new/detail.asp?id=3254. Accessed 15 October 2012.
87. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, et al. (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271: 4077-4081.
88. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, et al. (1996) Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271: 20631-20635.
89. Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, et al. (1996) Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 16: 6021-6037.
90. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452.
91. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54.
92. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F, (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20.
93. Masliah E, Hansen L, Adame A, Crews L, Bard F, et al. (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64: 129-131.
94. Kokjohn TA, Roher AE, (2009) Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets 8: 88-97.
95. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, et al. (2012) Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease. Arch Neurol 69: 1002-1010.
96. Lleo A, Berezovska O, Growdon JH, Hyman BT, (2004) Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry 12: 146-156.
97. Wolfe MS, (2007) When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8: 136-140.
98. Maarouf CL, Daugs ID, Spina S, Vidal R, Kokjohn TA, et al. (2008) Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener 3: 20.
99. Van Vickle GD, Esh CL, Kokjohn TA, Patton RL, Kalback WM, et al. (2008) Presenilin-1 280Glu->Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer's disease. Mol Med 14: 184-194.